Halozyme Therapeutics (HALO) Payables (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Payables of $14.1 million for Q1 2026, down 29.77% year-over-year from $20.1 million in Q1 2025, and down 32.54% quarter-over-quarter from $20.9 million in Q4 2025.
Halozyme Therapeutics (HALO) Payables (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Payables for 17 consecutive years, with $14.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 29.77% year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at $14.1 million (down 29.77% YoY), while the FY2025 annual figure was $20.9 million, up 103.91% from the prior year.
- Payables declined to $14.1 million in Q1 2026 per HALO's latest filing, from $20.9 million in the prior quarter.
- Across five years, Payables topped out at $20.9 million in Q4 2025 and bottomed at $1.3 million in Q1 2022.
- Historically, Payables has averaged $14.1 million across 5 years, with a median of $14.1 million in 2026.
- Annual changes were most pronounced in 2022 — Payables jumped 1048.15% — and 2024, when it sank 35.82%.
- Halozyme Therapeutics' Payables stood at $17.7 million in 2022, then sank by 33.22% to $11.8 million in 2023, then declined by 13.26% to $10.2 million in 2024, then surged by 103.91% to $20.9 million in 2025, then plunged by 32.54% to $14.1 million in 2026.
- Business Quant data shows HALO's Payables at $14.1 million in Q1 2026, $20.9 million in Q4 2025, and $15.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 23.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.61 Mn |
| Mar 31, 2026 | 14.10 Mn |
| Dec 31, 2025 | 20.90 Mn |
| Sep 30, 2025 | 15.36 Mn |
| Jun 30, 2025 | 18.69 Mn |
| Mar 31, 2025 | 20.07 Mn |
| Dec 31, 2024 | 10.25 Mn |
| Sep 30, 2024 | 12.40 Mn |
| Jun 30, 2024 | 15.43 Mn |
| Mar 31, 2024 | 13.33 Mn |
| Dec 31, 2023 | 11.82 Mn |
| Sep 30, 2023 | 19.32 Mn |
| Jun 30, 2023 | 10.12 Mn |
| Mar 31, 2023 | 8.70 Mn |
| Dec 31, 2022 | 17.69 Mn |
| Sep 30, 2022 | 18.17 Mn |
| Jun 30, 2022 | 12.23 Mn |
| Mar 31, 2022 | 1.27 Mn |
| Dec 31, 2021 | 1.54 Mn |
| Sep 30, 2021 | 3.32 Mn |